Q-omics provides the consensus-scored ANKRD61 profile across patient tissues and cancer cell-line models. ANKRD61 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD61 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ANKRD61 RNA expression shows 19,858 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where ANKRD61 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD61 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD61 survival associations across molecular data types. ANKRD61 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD61 RNA expression–survival associations across cancer types. High ANKRD61 expression shows unfavorable associations in UVM, CESC, KICH, LGG and THCA, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD61 RNA expression.
This table summarizes ANKRD61 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD61. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD61 shows higher tumor expression in KIRC, BLCA, LIHC, HNSC, LUAD and STAD. The KIRC box plot shows higher ANKRD61 RNA expression in tumor versus normal tissue (log2 FC = +0.226, t-test p < 0.001).
This table shows molecular features associated with ANKRD61 in patient tissues and cancer cell lines. In patient samples, ANKRD61 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD61 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
